Table 2.
Public health and economic impact of the QIV strategy compared to TIV
| QIV strategy vs TIV strategy | |
|---|---|
| Incremental costs (R$) | |
| Public payer direct costs | 193,738,203 |
| Public payer direct costs (discounted) | 168,840,170 |
| Direct costs (public & private) + societal costs | 90,041,085 |
| Direct costs (public & private) + societal costs (discounted) | 86,320,015 |
| Incremental health outcomes | |
| Life year saved | 7762 |
| Life year saved (discounted) | 3398 |
| QALY saved | 10,484 |
| QALY saved (discounted) | 6301 |
| ICER (R$ per LY gained. Ref: current strategy) | |
| Public payer perspective | 24,960 |
| Public payer perspective (discounted) | 49,692 |
| Societal perspective | 11,600 |
| Societal perspective (discounted) | 25,405 |
| ICER (R$ per QALY gained, ref: current strategy) | |
| Public payer perspective | 18,480 |
| Public payer perspective (discounted) | 26,798 |
| Societal perspective | 8589 |
| Societal perspective (discounted) | 13,700 |
ICER Incremental cost-effectiveness ratio, QALY Quality-adjusted life-year